Virtuoso Surgical Robotic System Receives FDA Breakthrough Device Designation

Virtuoso Surgical receives FDA Breakthrough Device Designation, positioning company at forefront of early diagnosis and ...
MedTech Dive

Medtronic expands AI, robotics hub in London; Virtuoso robot gets FDA breakthrough status

The Medtronic center will facilitate surgeon collaboration and AI-powered decision support. At Virtuoso Surgical, a robotic ...
Nature

Bladder Cancer Treatment Techniques

Bladder cancer treatment techniques have evolved considerably over recent decades, with surgical management remaining at the forefront. Historically, transurethral resection of bladder tumour (TURBT) ...
MassDevice

Virtuoso Surgical wins FDA breakthrough device designation for surgical robot

Virtuoso Surgical announced today that it received FDA breakthrough device designation for bladder lesion removal with its ...
European Medical Journal

Bladder Cancer Organoids and Personalised Therapies

Discover a study exploring how bladder cancer organoids advance personalised drug testing, reveal tumour heterogeneity, and ...
Business Wire

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade ...

18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) Data unveiled during a Podium Presentation at the American ...
Hosted on MSN

Novel Chemo Device for Early Bladder Cancer Wins FDA Approval

The FDA approved a gemcitabine intravesical system (Inlexzo) for adults with non-muscle-invasive bladder cancer (NMIBC), the agency announced on Tuesday. The indication for the nucleoside metabolic ...
Business Wire

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

UGN-301 was tolerated across all dose levels, with no dose-limiting toxicities or adverse events leading to treatment discontinuation UGN-301 formulated in a reverse thermal gel allowed sustained ...